ACS 化学神经科学分子聚焦：维拉唑酮（Vilazodone）。
ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).
机构信息
Department of Pharmacology and Chemistry and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, United States.
出版信息
ACS Chem Neurosci. 2011 Oct 19;2(10):554. doi: 10.1021/cn200084v.
Abstract
On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.
摘要
2011 年 1 月 21 日，美国食品和药物管理局批准了由 Clinical Data, Inc. 开发的新型选择性 5-羟色胺再摄取抑制剂（SSRI）——Viibryd，用于治疗成年人的重度抑郁症。
相似文献
1
ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).ACS 化学神经科学分子聚焦：维拉唑酮（Vilazodone）。
ACS Chem Neurosci. 2011 Oct 19;2(10):554. doi: 10.1021/cn200084v.
2
Vilazodone (Viibryd)--a new antidepressant.维拉唑酮（维思通）——一种新型抗抑郁药。
Med Lett Drugs Ther. 2011 Jul 11;53(1368):53-4.
3
Vilazodone approved for major depression.维拉唑酮获批用于治疗重度抑郁症。
Am J Health Syst Pharm. 2011 Mar 1;68(5):366. doi: 10.2146/news110009.
4
Vilazodone: a novel antidepressant.维拉唑酮：一种新型抗抑郁药。
Am J Health Syst Pharm. 2012 Sep 15;69(18):1551-7. doi: 10.2146/ajhp110374.
5
Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.盐酸维拉佐酮，一种用于治疗重度抑郁症的5-羟色胺再摄取抑制剂（SSRI）与5-羟色胺1A受体激动剂的复方制剂。
Consult Pharm. 2012 Dec;27(12):857-67. doi: 10.4140/TCP.n.2012.857.
6
Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.维拉唑酮使成年重度抑郁症患者获得早期且持续的改善：两项III期试验的事后分析
Curr Med Res Opin. 2014 Feb;30(2):263-70. doi: 10.1185/03007995.2013.855188. Epub 2013 Oct 31.
7
A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.一项为期 1 年的开放性研究，评估维拉佐酮治疗重度抑郁症患者的安全性和耐受性。
J Clin Psychopharmacol. 2011 Oct;31(5):643-6. doi: 10.1097/JCP.0b013e31822c6741.
8
Vilazodone: in major depressive disorder.维拉佐酮：用于治疗重度抑郁症。
CNS Drugs. 2011 Jul;25(7):615-27. doi: 10.2165/11207550-000000000-00000.
9
A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.一项关于用于治疗重度抑郁症的血清素能药物维拉唑酮的随机、双盲、安慰剂对照、8 周研究。
J Clin Psychiatry. 2011 Apr;72(4):441-7. doi: 10.4088/JCP.10m06596.
10
Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.伏硫西汀20毫克和40毫克治疗重度抑郁症的疗效与安全性：一项随机、双盲、安慰剂对照试验
Int Clin Psychopharmacol. 2015 Mar;30(2):67-74. doi: 10.1097/YIC.0000000000000057.
引用本文的文献
1
Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.伏硫西汀用于成人重度抑郁症：药理学概况及临床实践的最新综述
Neuropsychiatr Dis Treat. 2022 Jun 14;18:1175-1193. doi: 10.2147/NDT.S279342. eCollection 2022.
2
The faster-onset antidepressant effects of hypidone hydrochloride (YL-0919).盐酸依匹哌唑（YL-0919）更快的抗抑郁作用。
Metab Brain Dis. 2019 Oct;34(5):1375-1384. doi: 10.1007/s11011-019-00439-8. Epub 2019 Jun 24.
3
The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.维拉唑酮治疗重度抑郁症的临床前及临床疗效
Expert Opin Drug Discov. 2016;11(5):515-23. doi: 10.1517/17460441.2016.1160051. Epub 2016 Mar 16.
本文引用的文献
1
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.维拉佐酮治疗重度抑郁症的疗效和耐受性证据：一项随机、双盲、安慰剂对照试验。
J Clin Psychiatry. 2009 Mar;70(3):326-33. doi: 10.4088/jcp.08m04637. Epub 2009 Mar 10.
2
Risk factors and predictors of compliance in depression.抑郁症治疗依从性的风险因素及预测指标
Eur Neuropsychopharmacol. 2003 Sep;13 Suppl 3:S69-75. doi: 10.1016/s0924-977x(03)00095-6.
3
Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.5-（4-[4-（5-氰基-3-吲哚基）丁基]-丁基）-1-哌嗪基）-苯并呋喃-2-甲酰胺（EMD 68843）的行为和神经化学作用：一种5-羟色胺再摄取的联合选择性抑制剂和5-羟色胺（1A）受体部分激动剂
J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. doi: 10.1124/jpet.102.034280.
4
EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.EMD 68843，一种具有选择性突触前5-羟色胺1A受体激动特性的5-羟色胺再摄取抑制剂。
Eur J Pharmacol. 1997 Mar 19;322(2-3):147-53. doi: 10.1016/s0014-2999(96)00999-5.
Zotero 插件